CD86 and neoplasm: In addition to the reduction of macrophage accumulation in tumor sites as expected from FROUNT function, we also found impaired activation of macrophages due to Frount deficiency, accompanied by reduced expression of M1-like macrophage markers, such as CD86 and MHC class II, and impaired expression of M2 macrophage markers.